Patents by Inventor Deqian Bian

Deqian Bian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Resolution method for axis chiral enantiomers of lesinurad
    Patent number: 11365180
    Abstract: A resolution method of axial chiral enantiomers of lesinurad (2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid) adopts inexpensive and readily available quinoline natural products and derivatives thereof, such as quinine, cinchonine, quinidine or cinconidine as resolving agents to react with lesinurad racemate in an organic solvent to form a salt, and the salt is dissociated by acidification so as to obtain optically pure (R)- or (S)-2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid. The method can give axial chiral enantiomer of lesinurad in R configuration with a chiral purity ee of up to 100% and a total yield of 90% or more. The obtained axial chiral enantiomer of lesinurad in S configuration can reach a chiral purity ee of up to 99.9% and a total yield of 80% or more.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: June 21, 2022
    Assignee: CHINA RESOURCES SAIKE PHARMACEUTICAL CO., LTD.
    Inventors: Deqian Bian, Moyi Liu, Yan Yang, Fangze Chi
  • RESOLUTION METHOD FOR AXIS CHIRAL ENANTIOMERS OF LESINURAD
    Publication number: 20210053928
    Abstract: A resolution method of axial chiral enantiomers of lesinurad (2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid) adopts inexpensive and readily available quinoline natural products and derivatives thereof, such as quinine, cinchonine, quinidine or cinconidine as resolving agents to react with lesinurad racemate in an organic solvent to form a salt, and the salt is dissociated by acidification so as to obtain optically pure (R)- or (S)-2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid. The method can give axial chiral enantiomer of lesinurad in R configuration with a chiral purity ee of up to 100% and a total yield of 90% or more. The obtained axial chiral enantiomer of lesinurad in S configuration can reach a chiral purity ee of up to 99.9% and a total yield of 80% or more.
    Type: Application
    Filed: April 26, 2019
    Publication date: February 25, 2021
    Inventors: Deqian BIAN, Moyi LIU, Yan YANG, Fangze CHI
  • Purine inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 10221178
    Abstract: The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: March 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Meredeth Ann McGowan, Hua Zhou, Jason D. Katz, Lihu Yang, Joey L. Methot, Kathryn Ann Lipford, Shimin Xu, Ning Fu, Guoquan Xu, Deqian Bian, Jianmin Fu, Yabin Li, Kin Chiu Fong
  • Purine Inhibitors of Human Phosphatidylinositol 3-Kinase Delta
    Publication number: 20180141947
    Abstract: The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Application
    Filed: June 24, 2016
    Publication date: May 24, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Meredith Ann McGowan, Hua Zhou, Jason D. Katz, Lihu Yang, Joey L. Methot, Kathryn Ann Lipford, Shimin Xu, Ning Fu, Guoquan Xu, Deqian Bian, Jianmin Fu, Yabin Li, Kin Chiu Fong